Business Wire

REPLY

23.4.2024 12:44:33 CEST | Business Wire | Press release

Share
REPLY S.p.A.: Shareholders’ Meeting Approves the 2023 Financial Statements

The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] today approved the Financial Statements for the financial year 2023, confirming the distribution of a gross dividend of €1.00 per share.

The dividend will be paid on 22 May 2024, with dividend date set on 20 May 2024 (record date on 21 May 2024).

2023 Financial Statement

The Reply Group closed the 2023 financial year with a consolidated turnover of €2,118.0 million, recording a 12.0% increase compared to €1,891.1 million in 2022.

Consolidated EBITDA was €325.1 million, up 3.5% compared to €340.3 million recorded in 2022 (growth yoy is 20% net of the release of COVID funds accounted in 2022).

EBIT, from January to December, was €292.7 million, up 2.5% compared to €285.5 million recorded in 2022 (growth yoy is 22.7% net of the release of COVID funds accounted in 2022).

The Group net profit was at €186.7 million. In 2022, the corresponding figure was €191.0 million.

The Shareholders’ Meeting also adopted the following resolutions:

Appointment of the Board of Directors and the Board of Statutory Auditors for the three-year period 2024-2026

The Shareholders' Meeting has appointed the new members of the Board of Directors and the Board of Statutory Auditors for the three-year period 2024-2026, based on the lists of candidates submitted by the shareholders.

The following have been appointed as Directors:

- Mario Rizzante (Chairman), Tatiana Rizzante, Filippo Rizzante, Marco Cusinato, Elena Maria Previtera, Daniele Angelucci, Domenico Giovanni Siniscalco (who declared that he meets the independence requirements provided for in Article 148 of the TUF and the Corporate Governance Code) and Patrizia Polliotto (who declared that she meets the independence requirements provided for in Article 148 of the TUF and the Corporate Governance Code), taken from the majority list submitted by the shareholder Alika S. r.l. (holder of a shareholding equal to 39.754% of Reply S.p.A.'s share capital), which obtained the highest number of votes (63.957% of votes obtained);

- Secondina Giulia Ravera and Federico Ferro-Luzzi, both of whom declared to possess the independence requirements foreseen by article 148 of the TUF and by the Corporate Governance Code, taken from the minority list presented by a group of Investors (holding a total shareholding equal to 3.968% of Reply S.p.A.'s share capital).

The new Board of Statutory Auditors appointed is composed of three Standing Auditors and two Alternate Auditors:

- Ciro Di Carluccio (Chairman) and Gabriella Chersicla (Alternate Auditor), who declared that they meet the independence requirements provided for by article 148 of the TUF and the Corporate Governance Code, taken from the minority list presented by a group of Investors (holding a total of 4.978% of Reply S.p.A.'s share capital);

- Piergiorgio Re (Standing Auditor), Donatella Busso (Standing Auditor), Stefano Barletta (Alternate Auditor), who declared they meet the independence requirements provided for by article 148 of TUF and the Corporate Governance Code, drawn from the majority list submitted by the shareholder Alika S.r.l. (owner of a 39.754% shareholding in Reply S.p.A.), which obtained the highest number of votes (63.821% of votes obtained).

The curricula vitae of the Directors and Statutory Auditors, as well as the additional documentation required by current regulations, are available in the investors section of the website www.reply.com

Approval of the Program for the Acquisition and/or Disposal of Treasury Shares

The Shareholders’ Meeting authorised a new share buyback program, while withdrawing the current one approved at the Shareholders’ Meeting of 20 April 2023: the main objective of this program is the purchase of shares to implement the stock incentive plans, transactions aimed at the acquisition of equity investments, extraordinary financial transactions and/or the conclusion of agreements with strategic partners.

The authorization has a duration of 18 months from the date of the resolution, for a maximum of 3,607,950 ordinary shares (equal to 9.64398% of the current share capital) with a nominal value of €0.13 each for a maximum nominal value of €469,033.5, within the limit of a maximum financial commitment of €450,000,000. The purchase price may not be lower than the nominal value (currently €0.13) and higher than the official trading price recorded on the MTA market on the day before the purchase, increased by 20%.

Approval of the Remuneration Report

The Shareholders' Meeting also approved Sections I and II of the Remuneration Report drafted pursuant to Article 123-ter of Legislative Decree 58/1998.

The manager in charge of drafting the company's financial reports, Dr Giuseppe Veneziano, declares in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company's records, ledgers and accounting records.

This press release is a translation, the Italian version will prevail.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240423780149/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Jeito Capital Hits Record $1.2 Billion (€1 Billion)1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients8.4.2026 08:15:00 CEST | Press release

This record closing is the largest raise ever achieved by a fully independent European fund dedicated to Biopharma, validating Jeito’s patient-driven investment strategy, its multidisciplinary, collaborative expertise spanning from science to commercialization of medicines, and value creationIn five years, Jeito Capital has tripled its assets under management to €1.6 billion, firmly establishing itself among the top-tier global Biopharma investorsJeito II will build on Jeito I’s proven and differentiated strategy, investing in the most promising clinical Biopharma companies which address unmet patient needs and severe diseases, accelerate breakthrough therapeutic innovation, and deliver transformative benefits for patientsThis fundraise represents significant momentum for European Biopharma, strengthening its financial firepower and expertise to develop the next generation of global champions Jeito Capital (“Jeito”), a global independent private equity fund dedicated to Biopharma, toda

Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics8.4.2026 07:00:00 CEST | Press release

Hyaluronic acid product for knee osteoarthritis available in the EU and Switzerland from May 2026 Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of its offering. Synocrom™ is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history. The reintroduction of

Murata Begins Mass Production of Seven Automotive MLCCs with World-leading Capacitance for Their Rated Voltage and Size, Supporting Stable Operation of In-vehicle Systems and Greater Design Flexibility8.4.2026 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has begun mass production of seven AEC-Q200-qualified multilayer ceramic capacitors (MLCCs) that achieve the world’s largest capacitance for a given rated voltage and size*, supporting stable operation of in-vehicle systems and greater design flexibility. Five parts in the GCM series are rated at 2.5-4 Vdc, targeting IC peripheral circuits in advanced driver assistance systems (ADAS) and autonomous driving (AD) applications. The remaining two MLCCs are rated at 25 Vdc for in-vehicle power line applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407486750/en/ [Murata Manufacturing Co., Ltd.] Seven automotive MLCCs In recent years, as ADAS and AD technologies advance, the number and performance level of systems installed in vehicles have continued to increase. As a result, demand for higher capacitance low-voltage MLCCs used around ICs has grown to e

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)7.4.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees. The equity awards were granted on April 1, 2026 and consisted of options to purchase an aggregate of 117,445 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 55,875 shares. The options have an exercise price per share equal to $5.62, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted s

SLB OneSubsea and Subsea7 Sign Collaboration Agreement with PETRONAS Suriname7.4.2026 22:05:00 CEST | Press release

Partnership enables early engagement to co-develop cost-effective solutions and accelerate subsea development in Suriname Global energy technology company SLB (NYSE: SLB) today announced the signing of a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331210557/en/ SLB OneSubsea has signed a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea soluti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye